Today: 18 November 2025
Subscribe
Browse Category

Mergers & Acquisitions News 6 November 2025 - 10 November 2025

Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Published: 10 November 2025 Summary: Dalata Hotel Group plc has been formally delisted this morning following the completion of its acquisition by a Pandox AB–Eiendomsspar AS consortium. Scandic Hotels Group has begun managing Dalata’s 56 hotels under an interim management agreement and intends to acquire the operating platform for €500 million after a carve‑out, while Pandox will retain 31 investment properties in Ireland and the UK under long‑term, revenue‑based leases once the separation is complete. pandox.se+3pandox.se+3Investegate+3 What changed today (10 November 2025) Deal at a glance Scandic’s role: manage now, buy later Effective 7 November 2025, Scandic assumed operational responsibility
10 November 2025
 ·  ·  ·  · 
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. Bristol Myers Squibb News Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding
9 November 2025
 ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1 Notably, Pfizer had already received early termination of the HSR waiting period from
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key takeaways What happened today Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the
8 November 2025
 ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. What happened today Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly
8 November 2025
 ·  ·  ·  ·  · 
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Comcast (CMCSA) Stock Today — Nov. 7, 2025: Sky–ITV Talks and a Potential WBD Bid Put M&A in Focus as Shares Hover Near $27

Published: November 7, 2025 Key takeaways Comcast stock price snapshot (Nov. 7, 2025) Comcast Corporation (NASDAQ: CMCSA) traded modestly lower today, holding near the $27 handle. As of 19:33 UTC (2:33 p.m. ET), the stock printed $27.28 after opening at $27.56, with volume around 20.9 million shares. Intraday, CMCSA ranged $27.02–$27.77, reflecting an active tape as investors reacted to fresh M&A headlines. For reference, CMCSA finished Thursday at $27.31, setting the baseline for today’s moves. MarketWatch What’s moving CMCSA today: two deal headlines 1) Sky–ITV talks in the U.K. ITV confirmed it is in preliminary discussions to sell its free‑to‑air
7 November 2025
 ·  ·  ·  · 
Marvell Technology Stock Soars on AI Boom: Latest Price, Hot News & 2025 Outlook

Marvell Technology (MRVL) Slides as SoftBank Takeover Buzz Fades — Stock News for November 7, 2025

Summary: Marvell Technology (NASDAQ: MRVL) traded lower on Friday after yesterday’s pop tied to reports that SoftBank explored a takeover earlier this year. Investors are now refocusing on fundamentals and the company’s next earnings catalyst in early December. MarketWatch+1 MRVL stock today: price action at a glance As of 19:27 UTC on November 7, 2025, MRVL changed hands at $88.64, down about 5% on the day. The session ranged between $85.12 and $94.16 after opening at $91.68. For context, Reuters lists a 52‑week range of $47.09–$127.48. Reuters What’s driving the move Takeover chatter hangover. On Thursday, multiple outlets relayed a
7 November 2025
 ·  ·  ·  ·  · 
Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

What happened Sweetgreen reported third‑quarter FY2025 revenue of $172.4 million, down 0.6% year over year. Same‑store sales fell 9.5%, driven by an 11.7% drop in traffic and product mix, partly offset by 2.2% of price increases. Digital remained a majority of sales (61.8%), with 35.3% coming through owned digital channels. Restaurant‑level profit margin compressed to 13.1% from 20.1% a year ago, and adjusted EBITDA swung to ‑$4.4M from +$6.8M. The company opened six net new restaurants in the quarter. Business Wire Management cut full‑year guidance, now expecting $682–$688M in revenue, comps of ‑8.5% to ‑7.7%, restaurant‑level margins of 14.5%–15%, and
7 November 2025
 ·  ·  ·  ·  · 
Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation Inc. (NYSE: ACHR) unveiled a multi‑pronged update tied to its third‑quarter results: a $650 million equity raise, a deal to acquire control of Los Angeles’ Hawthorne Airport for $126 million, fresh flight‑test milestones for its Midnight eVTOL, and the closing of its Lilium patent portfolio purchase. The stock traded around $8.88 mid‑day as investors digested the capital raise and airport plan. Archer Aviation+1 What happened today Why Hawthorne matters HHR’s location—near LAX, SoFi Stadium, the Intuit Dome, The Forum, and Downtown LA—makes it a strategic hub for short‑hop urban missions Archer is targeting ahead of the LA28 Olympic
7 November 2025
 ·  ·  ·  ·  · 
Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial, Inc. (NASDAQ: BHF) said this morning it has entered into a definitive agreement to be acquired by Aquarian Capital in an all‑cash deal valuing the company at approximately $4.1 billion, or $70.00 per share. The transaction would take the U.S. life insurer and annuity provider private and is expected to close in 2026, pending shareholder and regulatory approvals. Business Wire Key takeaways Deal details and timeline Under the definitive merger agreement, Aquarian will acquire all outstanding BHF common shares for $70 in cash. Preferred stock will remain outstanding with the same terms and dividends, and outstanding junior subordinated
6 November 2025
 ·  ·  ·  ·  · 
Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive, Inc. (Nasdaq: ASST)—the parent of Strive Asset Management, LLC—priced an upsized initial public offering of its Variable Rate Series A Perpetual Preferred Stock (“SATA Stock”) at $80 per share, expanding the deal to 2,000,000 shares for ~$160 million in expected gross proceeds. Settlement is slated for Monday, November 10, 2025, pending customary closing conditions. The preferred carries an initial 12% annual dividend, paid monthly beginning December 15, 2025, with a $100 stated amount and a framework that allows Strive to adjust the rate within defined limits. Barclays and Cantor are joint bookrunners, with Clear Street as co‑manager. Proceeds may
6 November 2025
 ·  ·  ·  ·  ·  · 
1 2 3 4 5 6 … 12
Go toTop